Lengua R.E.,Hope International Radiotherapy Center |
Gonzalez M.F.,Hope International Radiotherapy Center |
Barahona K.,Hope International Radiotherapy Center |
Ixquiac M.E.,Hope International Radiotherapy Center |
And 5 more authors.
Reports of Practical Oncology and Radiotherapy | Year: 2013
Aim: This study evaluates the acute toxicity outcome in patients treated with RapidArc for localized prostate cancer. Background: Modern technologies allow the delivery of high doses to the prostate while lowering the dose to the neighbouring organs at risk. Whether this dosimetric advantage translates into clinical benefit is not well known. Materials and methods: Between December 2009 and May 2012, 45 patients with primary prostate adenocarcinoma were treated using RapidArc. All patients received 1.8 Gy per fraction, the median dose to the prostate gland, seminal vesicles, pelvic lymph nodes and surgical bed was 80 Gy (range, 77.4-81 Gy), 50.4 Gy, 50.4 Gy and 77.4 Gy (range, 75.6-79.2 Gy), respectively. Results: The time between the last session and the last treatment follow up was a median of 10 months (range, 3-24 months). The incidence of grade 3 acute gastrointestinal (GI) and genitourinary (GU) toxicity was 2.2% and 15.5%, respectively. Grade 2 acute GI and GU toxicity occurred in 30% and 27% of patients, respectively. No grade 4 acute GI and GU toxicity were observed. Older patients (>median) or patients with V60 higher than 35% had significantly higher rates of grade ≥2 acute GI toxicity compared with the younger ones. Conclusions: RapidArc in the treatment of localized prostate cancer is tolerated well with no Grade >3 GI and GU toxicities. Older patients or patients with higher V60 had significantly higher rates of grade ≥2 acute GI toxicity. Further research is necessary to assess definitive late toxicity and tumour control outcome. © 2013 Greater Poland Cancer Centre.
Cabrera M.E.I.,Hope International Radiotherapy Center |
Montenegro E.O.,University of San Carlos of Guatemala |
Lucero J.F.,Hope International Radiotherapy Center |
Linares L.A.,Hope International Radiotherapy Center |
Cabrera J.M.I.,University of San Carlos of Guatemala
IFMBE Proceedings | Year: 2013
Volumetric Modulated Arc Therapy (VMAT) is a radiother-apy modality that optimizes more parameters than intensity modulated radiotherapy (IMRT), therefore it is necessary to have a higher level of quality control of equipment and specific treatment plans for patients. The aim of this paper was to perform a comprehensive comparison of VMAT and IMRT through a set of test developed by the Task Group 119, to show the differences between both dosimetry plans and evaluation of these delivery plans carried out at Hope International Radiotherapy Center, Guatemala. The treatment plans were generated on Varian RapidArc and IMRT optimizer, and delivered with a Clinac 2300CD linear accelerator provided with a Millenium MLC, also from Varian. All were delivered to a cilindrical phantom, VMAT and IMRT plans. The readings on the detector array are compared with doses interpolated to 1mm grid on ArcCheck geometry based on the exported matrix dose from the Eclipse treatment plan. The IMRT plans were optimized to achieve the plan goal on each test, using the gantry angles and recommendation according to the TG-119. In a conservative way, we created the VMAT plans to achieve the plans goal, using 2 arcs with Multitarget and Prostate and 3 arcs with Head & Neck, C-Shape and C-Shape Hard, this taking in account the way to create our clinical plans delivered to patients. © 2013 Springer-Verlag.